aTyr Pharma (NASDAQ:ATYR) Lowered to "Hold" Rating by Leerink Partnrs

Key Points

• aTyr Pharma has been downgraded by Leerink Partners from a "strong-buy" rating to a "hold" rating, reflecting a more cautious outlook from analysts.
• The stock currently holds a consensus rating of "Hold" with a consensus price target of $23.25, despite other firms like Jefferies maintaining a "buy" rating and raising the target price significantly.
• As of the latest earnings report, aTyr Pharma missed analysts' consensus EPS estimates, reporting ($0.22), indicating ongoing challenges in achieving profitability.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) was downgraded by equities researchers at Leerink Partnrs from a "strong-buy" rating to a "hold" rating in a research report issued to clients and investors on Monday,Zacks.com reports. Leerink Partnrs also issued estimates for aTyr Pharma's Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.68) EPS, Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.05) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.05) EPS and FY2026 earnings at ($0.24) EPS.

ATYR has been the topic of a number of other research reports. Cantor Fitzgerald cut shares of aTyr Pharma from an "overweight" rating to a "neutral" rating in a research report on Monday, September 15th. HC Wainwright cut shares of aTyr Pharma from a "buy" rating to a "neutral" rating in a research report on Monday, September 15th. Leerink Partners reissued a "market perform" rating on shares of aTyr Pharma in a research report on Monday, September 15th. Wells Fargo & Company reaffirmed an "equal weight" rating on shares of aTyr Pharma in a research report on Monday, September 15th. Finally, Wall Street Zen cut shares of aTyr Pharma from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. One research analyst has rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $23.25.

aTyr Pharma Trading Down 5.5%

aTyr Pharma stock traded down $0.06 during trading hours on Monday, reaching $0.99. 26,837,744 shares of the company's stock were exchanged, compared to its average volume of 16,429,491. The company has a quick ratio of 5.63, a current ratio of 5.63 and a debt-to-equity ratio of 0.01. The firm's 50 day simple moving average is $4.93 and its 200 day simple moving average is $4.29. aTyr Pharma has a twelve month low of $0.95 and a twelve month high of $7.29. The firm has a market capitalization of $97.22 million, a PE ratio of -1.24 and a beta of 1.01.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.04). Research analysts predict that aTyr Pharma will post -0.91 earnings per share for the current year.

Hedge Funds Weigh In On aTyr Pharma

Hedge funds have recently modified their holdings of the company. Octagon Capital Advisors LP increased its position in shares of aTyr Pharma by 294.7% during the first quarter. Octagon Capital Advisors LP now owns 3,552,000 shares of the company's stock valued at $10,727,000 after buying an additional 2,652,000 shares during the period. Woodline Partners LP bought a new position in shares of aTyr Pharma in the fourth quarter worth approximately $6,092,000. Millennium Management LLC lifted its position in aTyr Pharma by 334.5% during the first quarter. Millennium Management LLC now owns 1,599,041 shares of the company's stock valued at $4,829,000 after purchasing an additional 1,231,052 shares during the period. Geode Capital Management LLC lifted its position in aTyr Pharma by 126.1% during the second quarter. Geode Capital Management LLC now owns 2,098,076 shares of the company's stock valued at $10,639,000 after purchasing an additional 1,170,276 shares during the period. Finally, MAI Capital Management raised its position in aTyr Pharma by 306,100.0% in the first quarter. MAI Capital Management now owns 658,330 shares of the company's stock worth $1,988,000 after acquiring an additional 658,115 shares during the period. Hedge funds and other institutional investors own 61.72% of the company's stock.

aTyr Pharma Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.